FDA Expands Indication for Amivantamab in Lung Cancer

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after disease progression on or after an EGFR-TKI.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-expands-indication-amivantamab-lung-cancer-2024a1000h79?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost